ArticleMolecular therapy. Nucleic acids2025
MicroRNA-responsive ON-OFF hybrid mRNA switch for precise protein expression control.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Towards mRNA therapeutics 2.0.Nature reviews. Drug discovery · 2026Review
- Two Classes of Protein Therapeutics: Why Dose-Response Architecture Defines the Boundary of mRNA Medicines.Pharmaceutics · 2026Review
- Lipoic Acid Derivative/PEI Composite Nanoparticles Enable Efficient mRNA Delivery via Thiol-Mediated Cellular Uptake.Macromolecular bioscience · 2026Article
- Modular Scalable Synthetic Gene Circuits for Complex Functions Within Minimal Computational Layers in Human Cells.Nature communications · 2026Article
- Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions.International journal of molecular sciences · 2026Review
- Recent Developments in Lipid Nanoparticle-Mediated Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- "More" Artificial mRNAs: Beyond the Art of Nature.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Use of the Peptide Barcode Method for Efficient Screening of mRNA Expression Control Sequence.Mass spectrometry (Tokyo, Japan) · 2026Article
- Nanotechnology-Assisted Co-Delivery of Immunotherapeutic Agents for Targeting Ovarian Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Microenvironment-Activated Fe-MOF Nanoplatform Enables Controlled Doxorubicin Release and Ferroptosis-Associated Oxidative Damage in MCF-7 Breast Cancer Cells.International journal of nanomedicine · 2026Article
- From binary to synergy in precision mRNA therapeutics: Dual-microRNA-sensing mRNAs for modular logic control of protein expression.Molecular therapy. Nucleic acids · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA (mRNA) technology is gaining attention for its potential in developing next-generation therapeutics. However, developing effective protein expression control technologies to regulate mRNA translation, particularly in a cell type- and tissue-specific manner, remains challenging. To achieve enhanced precision in translational regulation, we developed a microRNA (miRNA)-sensing hybrid mRNA switch, integrating an ON-type switch, which activates translation by detecting specific miRNAs expressed in target cells, into an OFF-type switch, which represses translation by sensing another miRNA in non-target cells. We first investigated effective module sequences after the poly(A)-tail for the ON-type mRNA switch to ensure appropriate translational activation in response to target cell-specific miRNAs. Moreover, the hybrid mRNA switch with a dual miRNA-sensing system reduced expression leakage in non-target cells and enhanced ON/OFF selectivity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.